India‑based CRO delivering fast, compliant, and cost‑effective clinical trial execution across multiple therapeutic areas.

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

AI Company Overview

India‑based CRO delivering fast, compliant, and cost‑effective clinical trial execution across multiple therapeutic areas.

OncologyCardiologyNeurologyGastroenterologyImmunologyHerbal MedicineNutraceuticals

Technology Platform

A centralized operational model combined with a digital health suite for electronic data capture, remote monitoring, and real‑time analytics to streamline multi‑site clinical trials.

Opportunities

Rapid growth of India’s clinical research market and increasing demand for decentralized trial technologies offer D2L significant expansion potential.

Risk Factors

Regulatory changes, intense competition from larger global CROs, and the need for continual technology investment pose key risks.

Competitive Landscape

Competes with Indian CROs such as Syngene International, QuintilesIMS, and Global CROs; differentiation lies in its centralized operational model and integrated digital health platform.